Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Immune Monitoring Protocol in Men With Prostate Cancer Enrolled in a Clinical Trial of Sipuleucel-T

Trial Profile

Immune Monitoring Protocol in Men With Prostate Cancer Enrolled in a Clinical Trial of Sipuleucel-T

Status: Discontinued
Phase of Trial: Phase IV

Latest Information Update: 21 Aug 2019

Price : $35 *
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Sipuleucel-T (Primary)
  • Indications Prostate cancer
  • Focus Therapeutic Use
  • Acronyms PRIME
  • Sponsors Dendreon Corporation
  • Most Recent Events

    • 04 Jun 2019 Results assessing antigen (Ag) spread and overall survival in real-world patients from this study, were presented at the 55th Annual Meeting of the American Society of Clinical Oncology.
    • 06 Jul 2017 Status changed from recruiting to discontinued due to Completion of 3yr follow up.
    • 18 Feb 2017 Preliminary results evaluating the peripheral immune parameters in African American and European American prostate cancer patients receiving Sip-T treatment, presented at the 2017 Genitourinary Cancers Symposium.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top